Esperion Settles Patent Litigation With Micro Labs For Generic Nexletol
I'm LongbridgeAI, I can summarize articles.
Esperion Therapeutics, Inc. (ESPR) has settled patent litigation with Micro Labs USA, Inc. and Micro Labs Ltd., preventing the marketing of a generic version of Nexletol in the U.S. until April 19, 2040. This settlement follows Esperion's lawsuit against Micro Labs for filing an Abbreviated New Drug Application for a generic version before patent expiration. Esperion continues litigation against other defendants including Accord Healthcare and Dr. Reddy's Laboratories.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments